MD Nexus

Flucytosine

Indications

Aspergillus Endocarditis (see Aspergillus)

xxx

Candidemia (see Candida)

FDA Labeling
- Bloodstream Infection/Endocarditis/Urinary Tract Infection/Meningitis, Pulmonary) Caused by Susceptible Strains of Candida, in Combination with Other Antifungal Aagents
Generally, Flucytosine Should Not Be Used as Monotherapy, as Resistance May Rapidly Develop

Disseminated Cryptococcosis (see Cryptococcosis)

FDA Labeling
- Bloodstream Infection/Endocarditis/Urinary Tract Infection/Meningitis, Pulmonary) Caused by Susceptible Strains of Candida, in Combination with Other Antifungal Aagents
Generally, Flucytosine Should Not Be Used as Monotherapy, as Resistance May Rapidly Develop

Saccharomyces Cerevisiae (see Saccharomyces Cerevisiae)

Off-Label Use
Generally, Flucytosine Should Not Be Used as Monotherapy, as Resistance May Rapidly Develop

Vulvovaginal Candidiasis (Due to Candida Glabrata) (see Candida)

Off-Label Use
Generally, Flucytosine Should Not Be Used as Monotherapy, as Resistance May Rapidly Develop

Pharmacology

XXXXXX

xxx

Administration

Oral (PO)

Dose: XXX

Dose Adjustment

Hepatic:
Renal:

Use in Pregnancy (see Pregnancy)

Flucytosine is Metabolized to Fluorouracil, Which May Cause Adverse Events if Administered During Pregnancy

Use During Breast Feeding

Not Known if Flucytosine is Present in Breast Milk

Drug Interactions

Amphotericin B (see Amphotericin)
- Amphotericin May Enhance the Adverse/Toxic Effect(s) of Flucytosine (Risk C: Monitor Therapy)
- Amphotericin May Increase the Serum Concentration of Flucytosine (Risk C: Monitor Therapy)
Saccharomyces Boulardii (see Saccharomyces Cerevisiae)
- Antifungal Agents (Systemic or Oral) May Decrease the Therapeutic Effect of Saccharomyces Boulardii (Risk X: Avoid Combination)

Adverse Effects

Allergic/Immunologic Adverse Effects

Hypersensitivity Reaction

Clinical
- XXXX

Cardiovascular Adverse Effects

Cardiotoxicity

Clinical
- Chest Pain (see Chest Pain)
- Ventricular Dysfunction

Dermatologic Adverse Effects

Dermatologic Toxicity

Clinical
- Pruritus (see Pruritus)
- Rash
- Skin Photosensitivity
- Toxic Epidermal Necrolysis (TEN) (see Toxic Epidermal Necrolysis)
- Urticaria (see Urticaria)

Endocrinologic Adverse Effects

Hypoglycemia (see Hypoglycemia)

Epidemiology
- XXXX

Gastrointestinal Adverse Effects

Abdominal Pain (see Abdominal Pain)

Epidemiology
- XXXX

Anorexia (see Anorexia)

Epidemiology
- XXXX

Diarrhea (see Diarrhea)

Epidemiology
- XXXX

Duodenal Ulcer (see xxxx)

Epidemiology
- XXXX

Enterocolitis

Epidemiology
- XXXX

Gastrointestinal Hemorrhage (see Gastrointestinal Hemorrhage)

Epidemiology
- XXXX

Drug-Induced Hepatotoxicity (see Drug-Induced Hepatotoxicity)

Epidemiology
- XXXX

Nausea/Vomiting (see Nausea and Vomiting)

Epidemiology
- XXXX

Ulcerative Colitis (see Ulcerative Colitis)

Epidemiology
- XXXX

Xerostomia (see Xerostomia)

Epidemiology
- XXXX

Hematologic Adverse Effects

Hematologic Toxicity

Clinical
- Agranulocytosis/Leukopenia (see Leukopenia)
- Anemia (see Anemia)
- Aplastic Anemia (see xxxx)
- Bone Marrow Aplasia
- Pancytopenia (see Pancytopenia)
- Peripheral Eosinophilia (see Peripheral Eosinophilia)
- Thrombocytopenia (see Thrombocytopenia)

Neurologic Adverse Effects

Ataxia (see Ataxia)

Clinical
- XXXX

Neuropsychiatric Toxicity

Clinical
- Confusion (see Delirium)
- Hallucination
- Psychosis (see Psychosis)
- Sedation (see Obtundation-Coma)

Fatigue (see Fatigue)

Clinical
- XXXX

Headache (see Headache)

xxx

Parkinson-Like Syndrome (see Parkinsons Disease)

Clinical
- XXX

Peripheral Neuropathy (see Peripheral Neuropathy)

Clinical
- Paresthesias (see Paresthesias)

Seizures (see Seizures)

Clinical
- XXXX

Vertigo (see Vertigo)

Clinical
- XXXX

Weakness

Clinical
- XXXX

Otolaryngologic Adverse Effects

Hearing Loss (see Hearing Loss)

Epidemiology
- XXXX

Pulmonary Adverse Effects

Dyspnea (see Dyspnea)

Epidemiology
- XXXX

Renal Adverse Effects

Acute Kidney Injury (AKI) (see Acute Kidney Injury)

Epidemiology
- XXXX

Crystalluria

Epidemiology
- XXXX

Hypokalemia (see Hypokalemia)

xxx

Other Adverse Effects

Fever (see Fever)

Epidemiology
- XXXX

References

General

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014;69(5):1162-1176. doi:10.1093/jac/dkt508 [MEDLINE]